Tokyo (Japan), Hilversum (Netherlands), Oslo (Norway), Mannheim (Germany), March 31, 2023 – NEC Corporation (NEC) announced in 2019 that it would expand the application of its cutting-edge AI technologies to drug development, focusing on advanced therapy as part of enhancing its healthcare business. Subsequently, in order to advance AI-powered personalized treatment and beyond, NEC acquired Norway-based NEC OncoImmunity...
The post NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business appeared first on Industry Analysts, Inc..
More...
The post NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business appeared first on Industry Analysts, Inc..
More...